REDWOOD CITY, Calif.,
Aug. 15, 2019 /PRNewswire/
-- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty
pharmaceutical company focused on the development and
commercialization of innovative therapies for use in medically
supervised settings, today announced that Dr. Pamela Palmer, Chief Medical Officer, will be
presenting at the 2019 Military Health System Research Symposium
(MHSRS). AcelRx was selected to present at one of the two
plenary sessions at this year's meeting. The presentation is
entitled "Pooled Safety Analysis of Patients Who Were Exposed to
< 300 mcg vs. ≥300 mcg of Sublingual Sufentanil in a 24 Hour
Period for Treatment of Acute Pain."
Details of the event are as follows:
MHSRS Plenary Session A
Date: Wednesday, August 21, 2019
Location: Gaylord Palms Convention Center, Kissimmee, FL
Presentation Time: 9:25am ET
About the Military Health System Research Symposium
(MHSRS)
The MHSRS is the Department of Defense's premier scientific
meeting. It provides a venue for presenting new scientific
knowledge resulting from military-unique research and development.
The MHSRS is the only military or civilian meeting that focuses
specifically on the unique medical needs of the Warfighter.
The MHSRS provides a collaborative setting for the exchange
of information between military providers with deployment
experience, research and academic scientists, international
partners, and industry on research and related Warfighter
healthcare initiatives. The MHSRS is an annual four-day
educational symposium that draws approximately 2,900 attendees.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company
focused on the development and commercialization of innovative
therapies for use in medically supervised settings. AcelRx's
proprietary, non-invasive sublingual formulation technology
delivers sufentanil with consistent pharmacokinetic profiles. The
Company has one approved product in the U.S.,
DSUVIA®(sufentanil sublingual tablet, 30 mcg), known as
DZUVEO in Europe, indicated for
the management of acute pain severe enough to require an opioid
analgesic for adult patients in certified medically supervised
healthcare settings, and one product candidate,
Zalviso®(sufentanil sublingual tablet system, SST
system, 15 mcg) being developed as an innovatively designed
patient-controlled analgesia (PCA) system for reduction of
moderate-to-severe acute pain in medically supervised settings.
DZUVEO and Zalviso are both approved products in Europe. In the U.S., Zalviso is an
investigational drug and not approved. For additional information
about AcelRx, please visit www.acelrx.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-selected-to-present-at-the-2019-military-health-system-research-symposium-300902659.html
SOURCE AcelRx Pharmaceuticals, Inc.